The Week in Review: December 8 – December 15, 2017

Friday, December 15, 2017 News Recap: 8 updates on liver transplantation outcomes for 2017: Over the past year, researchers and physicians have reported changes among the leading indications on the liver waitlist and improvements in transplantation outcomes. In this article, Healio.com/Hepatology presents recent reports on waitlist mortality risks, improved pediatric liver transplantation outcomes, and the positive effects of HCV treatment on transpl...

Liver cancer incidence after HCV therapy linked to risk factors, not treatment

Direct-acting antiviral treatment for hepatitis C did not correlate with an increased risk for hepatocellular carcinoma in a large cohort study of both treated and untreated patients with or without cirrhosis. Those with incident HCC after DAA treatment had higher risk factors at baseline. “There was no increased risk for HCC as a result of having received DAA therapy whatsoever,” Raymond T. Chung, PhD, director of Hepatology and Liver Center at Massachus

Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer?

People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) this month in Seattle. More HCC cases are being diagnosed among people with co-infection cured of h